Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.
EP: 1.Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC
EP: 2.Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer
EP: 3.Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 4.Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities
EP: 5.Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer
EP: 6.Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC
EP: 7.Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC
EP: 8.Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC
EP: 9.Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC
EP: 10.Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC
EP: 11.Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
EP: 12.Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the utility of mobocertinib (formerly TAK-788) in patients with non–small cell lung cancer (NSCLC) who harbor EGFR exon 20 insertions.
Mobocertinib is an oral TKI that has demonstrated significant efficacy among patients with NSCLC and EGFR exon 20 insertion mutations, says Piotrowska. During the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer, findings from a phase 1/2 study of mobocertinib in this patient population were presented and revealed an objective response rate of 26% per an independent review committee and 35% per investigator assessment. The median progression-free survival was 7.3 months.
Although these results are encouraging, toxicity remains a concern with mobocertinib, as well as other emerging targeted therapies for this subset of patients, Piotrowska says. In the study, 90% of patients reported diarrhea and 45% reported rash as treatment-related adverse effects. Moreover, 21% of patients experienced grade 3 or higher diarrhea. As such, improvements in symptom management or development of novel therapies that are less toxic are needed, concludes Piotrowska.
